Syntekabio to Showcase AI-Driven Drug Discovery Innovations at BioTechX USA Conference
TL;DR
Syntekabio is the Title Sponsor and will give a keynote address at BioTechX USA, positioning itself as a leader in AI-driven drug development.
Syntekabio's AI-driven technologies enable pharmaceutical and biotech companies to test the validity of target proteins without upfront costs, followed by STB LaunchPad program for delivering validated results.
Syntekabio's AI-driven solutions improve and accelerate R&D activities, offering potential hits and optimized leads in drug discovery, antibody prediction, and cancer neoantigen discovery to develop novel and effective therapeutics.
Syntekabio's participation at BioTechX USA includes a keynote presentation on addressing data scarcity in drug discovery with AI models, and a session on flexible molecular docking for neoantigen and antibody drug prediction.
Found this article helpful?
Share it with your network and spread the knowledge!
Syntekabio, a leader in artificial intelligence-driven drug development, will serve as Title Sponsor at the BioTechX USA conference in Philadelphia from September 17-18, 2024, demonstrating advanced AI solutions that are revolutionizing pharmaceutical research. The company's participation comes as AI integration in drug discovery gains momentum, highlighting the technology's growing importance in accelerating research and development processes. Dr. Jongsun Jung, CEO of Syntekabio, expressed enthusiasm about showcasing technologies that could improve and accelerate R&D activities through potential collaborations.
A key highlight of Syntekabio's presentation will be its innovative 'Develop Now, Pay Later' offer, which allows clients to validate target proteins without upfront costs, potentially removing financial barriers to early-stage drug discovery. This business model is supported by the company's STB LaunchPad program, powered by its proprietary DeepMatcher® technology platform, which delivers hits, optimized leads, and IND-enabled candidates with payment only upon delivery of validated results. The company's participation will include a keynote presentation by Dr. Jonathan Witztum, CTO of Syntekabio USA, titled 'Addressing Data Scarcity in Drug Discovery with Physics-based AI Models,' addressing one of the significant challenges in AI-driven drug discovery.
Additionally, Dr. Jongsun Jung will deliver a presentation on 'Flexible Molecular Docking for Neoantigen & Antibody Drug Prediction; Pre-Clinical Application,' showcasing capabilities in biologics discovery. The company will highlight its in silico biologics platforms, Neo-ARS™ and Ab-ARS™, which enable personalized or universal neoantigen cancer vaccine and novel antibody drug prediction respectively. Syntekabio's AI technology accesses over 10 billion known compounds and 1,400 in vitro/in vivo compatible drug targets covering over 70% of human diseases, powered by the company's AI Bio-Supercom Center with infrastructure of 5,000 servers, 40,000 CPU cores, and 2,500 GPUs.
The implications of Syntekabio's technologies extend beyond faster drug discovery to potentially more targeted and effective therapeutics through AI-driven identification of potential hits, optimization of small molecule leads, and prediction of antibodies and cancer neoantigens. This could lead to significant advancements in personalized medicine and cancer treatment as the pharmaceutical industry embraces AI technologies. Syntekabio's presence at BioTechX USA represents a significant step in bridging traditional drug discovery methods with cutting-edge AI solutions, highlighting AI's potential to transform drug development into faster, more efficient, and cost-effective processes for bringing new treatments to patients. Attendees can learn more by visiting Syntekabio's website or scheduling meetings at the conference.
Curated from News Direct
